Compare Recursion Pharmaceuticals Inc (RXRX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Zillow Group Inc Class A — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while Zillow Group Inc Class A trades at $29.87 (market cap $6.59B). The key difference: Zillow Group Inc Class A is far larger — about 3.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Zillow Group Inc Class A for 86 Days on average.
| RXRX | ZG | |
|---|---|---|
Market Cap | $2.14B | $6.59B |
Volume | 30,789,535 | 1,361,381 |
Sector | Health | Media |
52-Week High | $6.79 | $74.58 |
52-Week Low | $2.84 | $27.70 |
Typical Hold Time | 23 Days | 86 Days |
Enterprise Value | $1.66B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Zillow Group (ZG) trades at $29.9, up 6.9% over 24 hours, with a mixed technical outlook showing bullish oscillators but bearish moving averages. Fundamentally, the company reported a net income of $23 million in 2025, marking a return to profitability after losses in prior years, supported by revenue growth to $2.58 billion. Analyst sentiment is divided, with a consensus price target of $48.87, though recent news highlights competitive pressures and housing market headwinds.
The stock presents a turnaround opportunity as profitability improves, but risks include sensitivity to interest rates and real estate cycles. With nearly half of analysts rating it a buy, upside exists if execution continues, yet volatility from macroeconomic factors warrants caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
